Pill vs. shot: which blood thinner do bladder cancer patients prefer after surgery?

NCT ID NCT06243510

Completed Disease control Sponsor: Abramson Cancer Center at Penn Medicine Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This trial compared two blood thinners—apixaban (a pill) and enoxaparin (a shot)—in 126 bladder cancer patients after bladder removal surgery. The goal was to see which one patients were more likely to take as prescribed, which they preferred, and what it cost them. Participants took their assigned drug at home for 30 days and answered surveys by phone.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: apixaban and enoxaparin
What this could lead to: If successful, this could show that apixaban is easier for patients to take at home than enoxaparin after bladder cancer surgery, potentially improving clot prevention.
What could go wrong: This is a small, completed study focused on patient adherence and cost, not on directly proving which drug prevents more clots. Results may not apply to all bladder cancer patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

urinary bladder carcinoma Urinary Bladder Neoplasms venous thromboembolism prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BLADDER CANCER

Contacts and locations

Locations

Hospital of the University of Pennsylvania

Philadelphia, Pennsylvania, 19104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.